{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:28:23Z","timestamp":1786663703928,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 82370773"],"award-info":[{"award-number":["Grant No. 82370773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Physician Scientist Training Project, Beijing, China"},{"name":"National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital), Beijing, China"},{"name":"National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital), Beijing, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01066-4","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:47:52Z","timestamp":1766551672000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Yelin","family":"Mulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-0975","authenticated-orcid":false,"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-2599","authenticated-orcid":false,"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","volume":"519","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021;519:20\u20139.","journal-title":"Cancer Lett"},{"key":"1066_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","volume":"82","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82:584\u201398.","journal-title":"Eur Urol"},{"key":"1066_CR3","doi-asserted-by":"crossref","unstructured":"Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, et al. Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis. Eur Urol Oncol. 2024;7:179\u201388.","DOI":"10.1016\/j.euo.2023.07.013"},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"1066_CR5","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165\u201382.","journal-title":"CA Cancer J Clin"},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"113379","DOI":"10.1016\/j.ejca.2023.113379","volume":"195","author":"C Bosi","year":"2023","unstructured":"Bosi C, Bartha A, Galbardi B, Notini G, Naldini MM, Licata L, et al. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur J Cancer. 2023;195:113379.","journal-title":"Eur J Cancer"},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","volume":"16","author":"A Lopez de Sa","year":"2023","unstructured":"Lopez de Sa A, Diaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jimenez C, Paniagua-Herranz L, Sanvicente A, et al. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned. J Hematol Oncol. 2023;16:118.","journal-title":"J Hematol Oncol"},{"key":"1066_CR8","doi-asserted-by":"crossref","unstructured":"Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers. Cancers. 2023;15:1845.","DOI":"10.3390\/cancers15061845"},{"key":"1066_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fonc.2018.00653","volume":"8","author":"A Cimadamore","year":"2018","unstructured":"Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, et al. New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen. Front Oncol. 2018;8:653.","journal-title":"Front Oncol"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","volume":"26","author":"MD Galsky","year":"2008","unstructured":"Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2147\u201354.","journal-title":"J Clin Oncol"},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","volume":"96","author":"RS Hubert","year":"1999","unstructured":"Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA. 1999;96:14523\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1066_CR12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer. Mol Cancer Ther. 2020;19:2235\u201344.","journal-title":"Mol Cancer Ther"},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2025.06.013","volume":"88","author":"A Cimadamore","year":"2025","unstructured":"Cimadamore A, Boixareu C, Sharp A, Beltran H, de Bono JS. Novel therapeutic strategies for metastatic prostate cancer care. Eur Urol. 2025;88:437\u201348.","journal-title":"Eur Urol"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"1066_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148\u201356.","journal-title":"Ann Oncol"},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/07388550701334212","volume":"27","author":"L Nie","year":"2007","unstructured":"Nie L, Wu G, Culley DE, Scholten JC, Zhang W. Integrative analysis of transcriptomic and proteomic data: challenges, solutions and applications. Crit Rev Biotechnol. 2007;27:63\u201375.","journal-title":"Crit Rev Biotechnol"},{"key":"1066_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2023.41.4_suppl.671","volume":"41","author":"SP Thyparambil","year":"2023","unstructured":"Thyparambil SP, Liao W-L, Heaton R, Strasbaugh A, Melkie MA, Ling X. Proteomic profiling of antibody-drug conjugate (ADC) biomarkers in pancreatic cancer. J Clin Oncol. 2023;41:671.","journal-title":"J Clin Oncol"},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/1538-7445.AM2023-2160","volume":"83","author":"S Thyparambil","year":"2023","unstructured":"Thyparambil S, Liao W-L, Heaton R, Strasbaugh A, Melkie M, Ghafourian N, et al. Quantitative proteomics of antibody-drug conjugates and chemotherapy targets in prostate cancer. Cancer Res. 2023;83:2160.","journal-title":"Cancer Res"},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024;26:458\u201372.","journal-title":"Neuro Oncol"},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.","journal-title":"PLoS Med"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","volume":"15","author":"N Xu","year":"2022","unstructured":"Xu N, Yao Z, Shang G, Ye D, Wang H, Zhang H, et al. Integrated proteogenomic characterization of urothelial carcinoma of the bladder. J Hematol Oncol. 2022;15:76.","journal-title":"J Hematol Oncol"},{"key":"1066_CR22","doi-asserted-by":"crossref","unstructured":"Zou X, Lin X, Cheng H, Chen Y, Wang R, Ma M, et al. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. J Immunother Cancer. 2023;11:e006698.","DOI":"10.1136\/jitc-2023-006698"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MCSJ Garassino","year":"2024","unstructured":"Garassino MCSJ, Paz-Ares L, Lisberg A, Johnson M, P\u00e9rol M, Carroll D, et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01. J Thorac Oncol. 2024;19:S2\u2013S3.","journal-title":"J Thorac Oncol"},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14:2089\u2013108.","journal-title":"Cancer Discov"},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27:43\u201351.","journal-title":"Clin Cancer Res"},{"key":"1066_CR26","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1158\/1078-0432.CCR-20-1960","volume":"26","author":"PMR Pereira","year":"2020","unstructured":"Pereira PMR, Mandleywala K, Ragupathi A, Lewis JS. Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors. Clin Cancer Res. 2020;26:6215\u201329.","journal-title":"Clin Cancer Res"},{"key":"1066_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06393-z","volume":"15","author":"Y Mulati","year":"2025","unstructured":"Mulati Y, Shen Q, Tian Y, Chen Y, Yao K, Yu W, et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci Rep. 2025;15:23902.","journal-title":"Sci Rep"},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","volume":"60","author":"JA Carrasquillo","year":"2019","unstructured":"Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, et al. Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody. J Nucl Med. 2019;60:1517\u201323.","journal-title":"J Nucl Med"},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.5c00469","volume":"22","author":"W Huang","year":"2025","unstructured":"Huang W, Li L, Liang Y, Yang Q, Mixdorf JC, Engle JW, et al. ImmunoPET imaging of Nectin4 expression in gastric and bladder cancer using [(64)Cu]Cu-NOTA-Padcev. Mol Pharm. 2025;22:3468\u201378.","journal-title":"Mol Pharm"},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1021\/acs.molpharmaceut.5c00069","volume":"22","author":"W Huang","year":"2025","unstructured":"Huang W, Wang T, Chao F, Yang Q, Mixdorf JC, Li L, et al. ImmunoPET imaging of Trop2 expression in bladder cancer using [(64)Cu]Cu-NOTA-Trodelvy. Mol Pharm. 2025;22:2266\u201375.","journal-title":"Mol Pharm"},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.ccell.2024.06.003","volume":"42","author":"I Casanova-Salas","year":"2024","unstructured":"Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024;42:1301\u201312 e7.","journal-title":"Cancer Cell"},{"key":"1066_CR32","doi-asserted-by":"publisher","first-page":"1761072","DOI":"10.1080\/20013078.2020.1761072","volume":"9","author":"F Quaglia","year":"2020","unstructured":"Quaglia F, Krishn SR, Daaboul GG, Sarker S, Pippa R, Domingo-Domenech J, et al. Small extracellular vesicles modulated by alphaVbeta3 integrin induce neuroendocrine differentiation in recipient cancer cells. J Extracell Vesicles. 2020;9:1761072.","journal-title":"J Extracell Vesicles"},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"217184","DOI":"10.1016\/j.canlet.2024.217184","volume":"601","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang L, Cheng L, Wang Y, Li M, Yu J, et al. Extracellular vesicle-derived biomarkers in prostate cancer care: opportunities and challenges. Cancer Lett. 2024;601:217184.","journal-title":"Cancer Lett"},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1066_CR35","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","volume":"67","author":"TJ Roth","year":"2007","unstructured":"Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893\u2013900.","journal-title":"Cancer Res"},{"key":"1066_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101801","volume":"39","author":"FP Fabrizio","year":"2024","unstructured":"Fabrizio FP, Muscarella LA, Rossi A. B7-H3\/CD276 and small-cell lung cancer: what\u2019s new?. Transl Oncol. 2024;39:101801.","journal-title":"Transl Oncol"},{"key":"1066_CR37","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.2147\/IDR.S336212","volume":"14","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhang C, Zeng Y, Li Y, Huang S, Wang F, et al. Emergence and characterization of a ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone evolving moderate-level resistance to azithromycin in Shenzhen, China. Infect Drug Resist. 2021;14:4271\u20136.","journal-title":"Infect Drug Resist"},{"key":"1066_CR38","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.042","volume":"18","author":"M Johnson","year":"2023","unstructured":"Johnson M, Awad M, Koyama T, Gutierrez M, Falchook GS, Piha-Paul SA, et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1\/2 study. J Thorac Oncol. 2023;18:S54\u2013S5.","journal-title":"J Thorac Oncol"},{"key":"1066_CR39","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-08-2262","volume":"15","author":"G Chavin","year":"2009","unstructured":"Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, et al. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009;15:2174\u201380.","journal-title":"Clin Cancer Res"},{"key":"1066_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol. 2023;83:224\u201338.","journal-title":"Eur Urol"},{"key":"1066_CR41","doi-asserted-by":"publisher","first-page":"53 e23","DOI":"10.1016\/j.urolonc.2013.08.028","volume":"32","author":"IM Gomes","year":"2014","unstructured":"Gomes IM, Arinto P, Lopes C, Santos CR, Maia CJ. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol. 2014;32:53 e23\u20139.","journal-title":"Urol Oncol"},{"key":"1066_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041.","journal-title":"Nat Commun"},{"key":"1066_CR43","doi-asserted-by":"publisher","first-page":"1261070","DOI":"10.3389\/fimmu.2023.1261070","volume":"14","author":"HL Penny","year":"2023","unstructured":"Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, et al. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. Front Immunol. 2023;14:1261070.","journal-title":"Front Immunol"},{"key":"1066_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.euf.2021.02.006","volume":"7","author":"JT Nauseef","year":"2021","unstructured":"Nauseef JT, Bander NH, Tagawa ST. Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond. Eur Urol Focus. 2021;7:254\u20137.","journal-title":"Eur Urol Focus"},{"key":"1066_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Grullich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, et al. Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy. 2021;13:125\u201341.","journal-title":"Immunotherapy"},{"key":"1066_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, et al. Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov. 2024;14:76\u201389.","journal-title":"Cancer Discov"},{"key":"1066_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ymthe.2023.02.010","volume":"31","author":"L Zekri","year":"2023","unstructured":"Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, et al. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023;31:1033\u201345.","journal-title":"Mol Ther"},{"key":"1066_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I\/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1066_CR49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:1651\u20137.","journal-title":"Clin Cancer Res"},{"key":"1066_CR50","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41591-022-01742-1","volume":"28","author":"NP Tschernia","year":"2022","unstructured":"Tschernia NP, Norberg SM, Gulley JL. CAR T cells reach clinical milestone in prostate cancer. Nat Med. 2022;28:635\u20136.","journal-title":"Nat Med"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01066-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:03:52Z","timestamp":1786662232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01066-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01066-4","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The experiments involved in this study were approved by the Ethics Committee of Peking University First Hospital with exemption from informed consent (2023-289-001). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}